CBT
CABOT CORP
NYSE · Basic Materials · Chemicals - Specialty · US
$75.11
+4.32%Year over year
Reported trailing growth
- Revenue
- +0.8%
- EBITDA
- -35.2%
- EBIT
- -41.4%
- EPS
- -53.5%
- Free cash flow
- +0.0%
- Operating cash flow
- +0.0%
Forward estimates
Based on analyst estimates
- Revenue
- -1.3%
- EBITDA
- +57.4%
- EPS
- +153.5%
Three-year CAGR
- Revenue
- -4.9%
- EBITDA
- +13.9%
- EBIT
- +16.9%
- Net income
- +16.6%
- EPS
- +18.5%
- Free cash flow
- +5.5%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Sep 1, 2026